India shares higher at close of trade; Nifty 50 up 0.41%
Investing.com – India equities were higher at the close on Friday, as gains in the Capital Goods, Power and Metals sectors propelled shares higher. At the close in NSE, the Nifty 50 rose...
Strong Buy
or
Dr. Reddy’s Labs News & Analysis
-
-
India shares lower at close of trade; Nifty 50 down 0.71%
Investing.com – India equities were lower at the close on Friday, as losses in the Metals, Real Estate and Public Sector Undertakings sectors propelled shares lower. At the close in NSE,...
-
Sensex Clears Mount 55K; Nifty Over 16,500
By Aditya Raghunath Investing.com -- It was a day that made investors richer by Rs 1.35 lakh crore as the BSE Sensex 30 gained 593 points to cross 55K and closed at 55,437 while Nifty 50...
-
India shares higher at close of trade; Nifty 50 up 1.01%
Investing.com – India equities were higher at the close on Friday, as gains in the Technology, Capital Goods and IT sectors propelled shares higher. At the close in NSE, the Nifty 50 gained...
-
Markets Hit New Records; Investing in China Might Get Tougher
By Aditya Raghunath Investing.com -- The BSE Sensex 30 closed at a record 54,843, up 0.58% and Nifty 50 closed up 0.5% at 16,364. This strong closing by Nifty over 16,300 could spark the...
-
India shares higher at close of trade; Nifty 50 up 0.50%
Investing.com – India equities were higher at the close on Thursday, as gains in the Power, Capital Goods and IT sectors propelled shares higher. At the close in NSE, the Nifty 50 rose...
-
Dr Reddy's to sell US, Canada territory rights for migraine drug to BDSI
Drug firm Dr Reddy's Laboratories on Wednesday said it has entered into a definitive agreement with BioDelivery Sciences International, Inc., to sell its US and Canada territory...
-
Bharti Airtel, Tata Steel, Dr. Reddy's Labs in focus
Bharti Airtel reported a consolidated net profit of Rs 284 crore in Q1 FY22 as against a net loss of Rs 15,933 crore in Q1 FY21. Total revenues increased by 15.3% YoY to Rs 26,854 in the...
-
India shares lower at close of trade; Nifty 50 down 0.24%
Investing.com – India equities were lower at the close on Wednesday, as losses in the Auto, Banking and Real Estate sectors propelled shares lower. At the close in NSE, the Nifty 50 fell...
-
Sensex Recovers 640 Points, End 135 Points Lower
By Aditya Raghunath Investing.com -- Data will tell you that Nifty 50 fell 0.24% or 37 points and the BSE Sensex 30 closed lower by 0.26% or 135 points. However, the real story is that both...
-
Neutral on Dr. Reddy's Laboratories, target price Rs 5200: Motilal Oswal
Dr. Reddy's Laboratories Ltd., incorporated in the year 1984, is a Large Cap company (having a market cap of Rs 80574.04 Crore) operating in Pharmaceuticals sector.
-
China Fears Cause Volatility in Asia; Nifty, Sensex End Lower
By Aditya Raghunath Investing.com -- Another day, another fall, and the 15,900 mark remains out of reach for Nifty. This time it was the Dragon that sparked volatility in Asia and caused...
-
Why Dr Reddy’s Stock Fell 10% After Missing Q1 Estimates by 1%
By Aditya Raghunath Investing.com -- Dr. Reddy’s Laboratories Ltd (NS:REDY) reported its numbers for Q1 FY22. Net profit came in at Rs 570.8 crore compared to Rs 594.6 crore in the...
-
Dr Reddy's Labs Sheds 11% After Profit Falls To Rs 570 Crore In June Quarter
Dr Reddy's Share Price Today: On Tuesday, Dr Reddy's Labs opened on the BSE at Rs 5,421, inching to an intra day high of Rs 5,445, and an intra day low of Rs 4,786.26, so far
-
Dr Reddy's Laboratories consolidated net profit declines 36.02% in the June 2021 quarter
Sales rise 11.36% to Rs 4919.40 crore
-
India shares lower at close of trade; Nifty 50 down 1.07%
Investing.com – India equities were lower at the close on Monday, as losses in the Banking, Metals and Auto sectors propelled shares lower. At the close in NSE, the Nifty 50 lost 1.07%,...
-
India shares higher at close of trade; Nifty 50 up 0.76%
Investing.com – India equities were higher at the close on Tuesday, as gains in the Banking, Metals and Oil & Gas sectors propelled shares higher. At the close in NSE, the Nifty 50 rose...
-
Sputnik V soft launched in over 50 cities in India: Dr Reddy's Laboratories
Dr Reddys Laboratories Ltd, which soft-launched Russia's Covid-19 vaccine, Sputnik V here on May 14 has expanded the pilot project to over 50 other cities and towns in the country
-
Buy Dr. Reddy's Laboratories, target price Rs 5604: ICICI Direct
Dr. Reddy's Laboratories Ltd., incorporated in the year 1984, is a Large Cap company (having a market cap of Rs 92746.20 Crore) operating in Pharmaceuticals sector.
-
India shares higher at close of trade; Nifty 50 up 0.71%
Investing.com – India equities were higher at the close on Monday, as gains in the Real Estate, Metals and Banking sectors propelled shares higher. At the close in NSE, the Nifty 50 rose...
-
Markets Close Down on Selling Pressure in IT and Financials; Crude Close to $75
By Aditya Raghunath Investing.com -- Nifty 50 and the BSE Sensex 30 closed down for the fourth consecutive day as there was heavy selling pressure in IT and financials segment. Bajaj Finserv...
-
India shares lower at close of trade; Nifty 50 down 0.26%
Investing.com – India equities were lower at the close on Thursday, as losses in the Power, Technology and IT sectors propelled shares lower. At the close in NSE, the Nifty 50 declined...
-
Dr Reddy's Labs denied approval for final trial of Russian-made Sputnik Light
"The subject expert committee (SEC), a body under the drug regulator, did not find any "scientific rationale" to conduct phase-3 trials and hence did not consider Dr Reddy's application...
-
Barometers trade near day's high; breadth remains strong
The benchmark indices continued trading higher in early afternoon trade. The Nifty was hovering above 15,800 level. Pharma stocks were in demand.
-
Cipla, Dr Reddy's Labs: Tech charts show up to 11% rally in pharma stocks
After hitting a new all-time high of Rs 997 earlier today, the stock of Cipla is all set to rally towards Rs 1,100
-
Five drug makers collaborate for clinical trial of Molnupiravir
Cipla, Dr Reddy's Laboratories, Emcure Pharmaceuticals, Sun Pharmaceutical Industries & Torrent Pharmaceuticals will collaborate for the clinical trial of investigational oral anti-viral...
-
Buy Dr. Reddy's Laboratories, target price Rs 5700: Yes Securities
Dr. Reddy's Laboratories Ltd., incorporated in the year 1984, is a Large Cap company (having a market cap of Rs 90353.12 Crore) operating in Pharmaceuticals sector.
-
Maintain ‘add’ on Dr. Reddy’s Laboratories with target price of Rs 5,848
The target for reducing specific energy consumption was 31% and company could achieve 22% reduction. The share of renewable energy increased by 8.8% vs target of 16.2% and attained 72% water...
-
Nifty Falls as FM’s Rs 1.1 Lakh Crore Stimulus Fails to Boost Markets
By Aditya Raghunath Investing.com -- Finance Minister Nirmala Sitharaman announced a stimulus of Rs 1.1 lakh crore for COVID-affected sectors but that didn’t prevent a sell-off in IT and...
-
India shares lower at close of trade; Nifty 50 down 0.29%
Investing.com – India equities were lower at the close on Monday, as losses in the Capital Goods, Technology and IT sectors propelled shares lower. At the close in NSE, the Nifty 50...
-
Dr Reddy's Laboratories announces commercial launch of Covid-19 drug 2-DG
: Dr. Reddy's Laboratories Ltd on Monday announced the commercial launch of 2-deoxy-D-glucose (2-DG).
-
Dr. Reddy's Laboratories announces commercial launch of COVID-19 drug 2-DG
In the initial weeks, the company will make the drug available in hospitals across metros and Tier 1 cities, and subsequently expand coverage to the rest of the country.
-
Add Dr. Reddy's Laboratories, target price Rs 5848: ICICI Securities
Dr. Reddy's Laboratories Ltd., incorporated in the year 1984, is a Large Cap company (having a market cap of Rs 88294.31 Crore) operating in Pharmaceuticals sector.
-
Dr. Reddy’s Labs announces commercial launch of 2-DG used in treatment of Covid-19
Dr. Reddy’s will supply to major government as well as private hospitals across India.The maximum retail price (MRP) of each sachet has been fixed at Rs. 990, with a subsidized rate offered...
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
